TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cellectis SA ( (CLLS) ) just unveiled an announcement.
On December 8, 2025, Cellectis announced promising results from its Phase 1 NATHALI-01 clinical trial for eti-cel, an allogeneic dual CAR-T therapy targeting CD20 and CD22, at the American Society of Hematology meeting. The trial showed an 88% overall response rate and a 63% complete response rate in patients with relapsed/refractory non-Hodgkin lymphoma. The company plans to enhance these results by incorporating low dose Interleukin-2 (IL-2) support, with patient enrollment for this cohort starting in Q1 2026. These developments underscore Cellectis’ innovative approach to improving outcomes for difficult-to-treat cancer patients.
The most recent analyst rating on (CLLS) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is primarily influenced by its strong technical indicators, which suggest positive market momentum. However, the company’s financial performance and valuation are concerning due to persistent unprofitability and negative cash flow, which significantly impact the score.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company that utilizes a pioneering gene-editing platform to develop life-saving cell and gene therapies. The company focuses on creating allogeneic CAR T immunotherapies for oncology, offering off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. Cellectis is one of the few companies with in-house manufacturing capabilities, controlling the entire cell and gene therapy value chain. The company is headquartered in Paris, France, with additional locations in New York and Raleigh, NC, and is listed on the Nasdaq Global Market and Euronext Growth.
Average Trading Volume: 148,060
Technical Sentiment Signal: Buy
Current Market Cap: $346.1M
Learn more about CLLS stock on TipRanks’ Stock Analysis page.